Central retinal artery occlusion following COVID-19 vaccine administration

Abdin, Alaa Din; Гартнер, Барбара; Seitz, Berthold

doi:10.1016/j.ajoc.2022.101430

Cited by 21 publications

(19 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kang et al reported a 64yo male who experienced a branch retinal artery occlusion three days after the first dose of the Biontech Pfizer vaccine (BPV) 7 . A 76yo female developed unilateral, painless visual loss 2 days after the first dose of the AZV 8 . Four patients experienced branch retinal artery occlusion 22.8 days on the average after the last vaccine dose application 9 .…”

mentioning

confidence: 99%

Retinal artery/vein occlusion complicating SARS-CoV-2 vaccinations

Finsterer¹

2022

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

mentioning

confidence: 99%

Retinal artery/vein occlusion complicating SARS-CoV-2 vaccinations

Finsterer¹

2022

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

“…Besides the abovementioned case series, other cases were reported as separate case reports with either adenoviral vector vaccine (three cases with AstraZeneca vaccines and one case with Sputnik V vaccine of Gamaleya Institute) [ 55 – 57 ] or mRNA vaccine (eight cases with Pfizer/BioNTech vaccines and two cases with Moderna vaccines) [ 15 , 16 , 58 – 64 ]. Among those who were vaccinated with mRNA vaccines, 70% presented ocular symptoms after the second dose [ 15 , 16 , 59 – 61 , 64 ].…”

Section: Resultsmentioning

confidence: 99%

“…Among those who were vaccinated with mRNA vaccines, 70% presented ocular symptoms after the second dose [ 15 , 16 , 59 – 61 , 64 ]. In contrast, two-thirds of patients vaccinated with adenoviral vector vaccines presented ocular symptoms at the first dose [ 55 ]. There was also a case of bilateral AMN and PAMM, reported after the second dose of adenoviral vector vaccine (CoviShield, formerly ChAdOx1 nCoV-10, AstraZeneca) [ 65 ].…”

Section: Resultsmentioning

confidence: 99%

Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review

Yeo

Kim

Lee

et al. 2023

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose Abnormal hypercoagulability and increased thromboembolic risk are common in patients with coronavirus disease (COVID-19). COVID-19 has been suggested to cause retinal vascular damage, with several studies on COVID-19 patients with retinal vascular occlusions. We reviewed and investigated studies on retinal vascular occlusions in patients diagnosed with COVID-19 and in those vaccinated for COVID-19. Methods Studies that reported retinal vascular occlusion in COVID-19 patients or in vaccinated people were identified using the terms “retinal occlusion,” together with “severe acute respiratory syndrome coronavirus 2”, “SARS-CoV-2,” “COVID-19,” “coronavirus,” and “vaccine,” through systematic searches of PubMed and Google Scholar databases until January 7, 2022. Results Thirteen cases of retinal artery occlusion (RAO) and 14 cases of retinal vein occlusion (RVO) were identified among patients diagnosed with COVID-19. Half of the patients with RAO or RVO revealed no systemic disorders except current or past COVID-19, and ocular symptoms were the initial presentation in five cases. Among patients with RAO, most presented with central RAO at 1–14 days of COVID-19 diagnosis, with abnormal coagulation and inflammatory markers. Among those with RVO, two-thirds presented with central RVO and one-third with RVO. Eleven cases with acute macular neuroretinopathy (AMN) and/or paracentral acute middle maculopathy (PAMM) were reported among patients with COVID-19, presenting scotoma resolved spontaneously in most cases. Among the 26 cases vaccinated with either mRNA or adenoviral vector vaccines for COVID-19 and presenting retinal vascular occlusions, there were more RVO cases than RAO cases, and ocular symptoms mostly occurred within 3 weeks after vaccination. One case presented bilateral AMN and PAMM after COVID-19 vaccination. Conclusion Retinal vascular occlusions might be a manifestation of COVID-19, although rare, especially in patients at risk of systemic hypercoagulability and thromboembolism. For COVID-19 vaccines, the causal relationship is controversial because there are few case reports of retinal vascular occlusions after COVID-19 vaccination.

show abstract

“…However, there is now a growing literature reporting single case reports with RVO after both mRNA vaccines including mRNA-1273 (Moderna) [ 12 ] and BNT162b2 (Pfizer) [ 13 – 16 ], and vector-based ChAdOx1 (Vaxzevria) [ 17 – 19 ]. Other single case reports have documented combined CRAO-CRVO shortly after mRNA-1273 (Moderna) [ 20 ], combined CRAO-CRVO with ischemic optic neuropathy after BNT162b2 (Pfizer) [ 21 ], and CRAO after ChAdOx1 (Vaxzevria) [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Retinal vascular occlusion and SARS-CoV-2 vaccination

Vujosevic

Limoli

Romano

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To assess the clinical and retinal imaging features of patients in whom retinal vascular occlusion (VO) had developed in temporal associations with COVID-19 vaccination. Methods In this retrospective case series, all consecutive adult patients with new onset VO within 6 weeks of vaccination against COVID-19 were included in the study between May 1 and October 31, 2021. All patients had a systemic medical health assessment, full ophthalmic evaluation, and complete fundus imaging. Results Fifteen eyes of VO (14 patients) after COVID-19 vaccinations were identified. The median time between vaccination and symptoms onset was 14 days (range 7–42 days). The mean best-corrected visual acuity (BCVA) was 20/55 with a range of 20/20 to 20/200. Eleven of 15 eyes (73.3%) had visual acuity improvement after intravitreal treatment at 60–90 days (range, 45–105 days) from the presentation. Four of 5 cases without systemic risk factors for VO had a mean BCVA > 20/32 at presentation and > 20/25 at the latest evaluation. Between May 1 and October 31, 2021, a temporal association was found between the 15 reported cases and COVID-19 vaccination out of a total of 29 VO (p = 0.05). The incidence of VO was higher in the considered period compared to the equivalent 6-month period in 2019 (1.17% vs 0.52%, respectively; p = 0.0134). Conclusions Retinal vascular occlusion with different grades of severity are reported in temporal association with COVID-19 vaccination. The exact pathogenic mechanism needs to be further studied. No certain causal relationship can be established from this case series.

show abstract

Central retinal artery occlusion following COVID-19 vaccine administration

Cited by 21 publications

References 8 publications

Retinal artery/vein occlusion complicating SARS-CoV-2 vaccinations

Retinal artery/vein occlusion complicating SARS-CoV-2 vaccinations

Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review

Retinal vascular occlusion and SARS-CoV-2 vaccination

Contact Info

Product

Resources

About